Login to Your Account



TiGenix Stem Cell Therapy Helps Refractory RA Patients

By Nuala Moran
Staff Writer

Wednesday, April 24, 2013
LONDON – TiGenix NV unveiled positive Phase IIa results for its Cx611 allogeneic stem cell therapy in the treatment of 53 rheumatoid arthritis patients whose disease was not responsive to disease-modifying anti-rheumatic drugs (DMARDS) or biologics.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription